Clinical Trial Update: Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update comparing Fingolimod efficacy in de novo Relapsing-Remitting Multiple Sclerosis patients versus those previously treated with a fi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• GILENYA (FINGOLIMOD HCL)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapsing Remitting Multiple Sclerosis | Phase 4 | Status: COMPLETED | Results posted: 2019-01-25